Among the recent advancements are glucagon-like peptide-1 (GLP-1) agonists and glucose-dependent insulinotropic peptide (GIP) dual agonists and once-weekly insulin, which offer promising avenues for diabetes management [5,6]. This evidence concerns the gene INS and diabetes mellitus.